Outlook Therapeutics rises after US FDA approves eye disease drug

Outlook Therapeutics

24/07/2026 20:34

** Shares of drugmaker Outlook Therapeutics OTLK.O rise 18% to $1.56
** U.S. FDA approves OTLK's drug, Lytenava, for wet age-related macular degeneration (AMD)
** AMD is a chronic eye disease that can cause blurred vision and blind spots and is a leading cause of blindness among older adults
** Approval marks Outlook's first commercial entry into the U.S. market and validates a years-long regulatory effort that included multiple FDA rejection letters
** Including session's move, shares down 23% YTD

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com))